Menu
PacPremier
Magic Hour
Montecito
Loading...
You are here:  Home  >  'Aranesp'
Latest

Amgen updates agreement with DaVita for dialysis treatment

By   /  Monday, January 9th, 2017  /  Central Coast Health Watch, Latest news, Tri-County Public Companies  /  Comments Off on Amgen updates agreement with DaVita for dialysis treatment

Thousand Oaks biotech company Amgen entered into a six-year supply agreement with DaVita for dialysis treatments, the company announced on Jan. 9. Under the terms of the new agreement, Amgen will supply DaVita with Epogen and Aranesp for agents to stimulate red blood cells in dialysis treatment in the United States and Puerto Rico. The Read More →

Read More →
Latest

Settlement ends Amgen drug kickback saga

By   /  Thursday, January 7th, 2016  /  Central Coast Health Watch, East Ventura County, Latest news, Tri-County Public Companies  /  Comments Off on Settlement ends Amgen drug kickback saga

A drug kickback program is finally behind Amgen, the Thousand Oaks-based pharmaceutical giant. Louisville, K.Y.-based PharMerica was the last of three companies to settle lawsuits relating to Amgen allegedly paying kickbacks to PharMerica and another company to prescribe patients the anemia drug Aranesp. PharMerica settled the suit for $2.5 million in December, Louisville Business First Read More →

Read More →
Latest

Amgen to pay $150M for misbranding Aranesp

By   /  Tuesday, December 18th, 2012  /  Latest news  /  Comments Off on Amgen to pay $150M for misbranding Aranesp

[Editor’s note: This story has been updated with comments from Amgen.] Biotech giant Amgen pleaded guilty Dec. 18 to a misdemeanor charge for misbranding its anemia drug Aranesp. According to a report from Bloomberg News, the Thousand Oaks-based firm agreed to pay $150 million in fines and penalties as part of the guilty plea. U.S. Read More →

Read More →
Latest

FDA OKs Aranesp for pre-dialysis patients

By   /  Monday, October 25th, 2010  /  Latest news, Technology  /  Comments Off on FDA OKs Aranesp for pre-dialysis patients

Amgen’s anemia treatment Aranesp is safe for kidney patients whose disease doesn’t require dialysis, a federal panel announced Oct. 18 in response to a study that found the drug could increase stroke risk in those patients. Outside advisers to the U.S. Food and Drug Administration said the treatment shouldn’t be withdrawn or limited to a Read More →

Read More →